S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Laser breakthrough could send stock soaring 2,467% (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Laser breakthrough could send stock soaring 2,467% (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Laser breakthrough could send stock soaring 2,467% (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
Laser breakthrough could send stock soaring 2,467% (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
10 Ways Entrepreneurs Can Navigate a Down Economy
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
PwC Australia sidelines 9 directors as leak of tax information investigated
South African president appoints judge to oversee weapons-for-Russia inquiry
[BREAKING] Small Firm Develops World's First Anti-Aircraft Laser (Ad)
Drought-struck Barcelona quenches thirst with costly desalination
Get the Most Out of Remote Meetings and Avoid Meeting Burn Out
NASDAQ:MNMD

Mind Medicine (MindMed) (MNMD) Stock Forecast, Price & News

$3.54
+0.19 (+5.67%)
(As of 05/26/2023 04:00 PM ET)
Compare
Today's Range
$3.31
$3.58
50-Day Range
$2.83
$3.95
52-Week Range
$2.12
$19.95
Volume
360,500 shs
Average Volume
488,824 shs
Market Capitalization
$136.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$26.67

Mind Medicine (MindMed) MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
653.3% Upside
$26.67 Price Target
Short Interest
Bearish
10.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.54mentions of Mind Medicine (MindMed) in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$41,594 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.07) to ($1.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.93 out of 5 stars

Medical Sector

806th out of 1,010 stocks

Medicinals & Botanicals Industry

9th out of 12 stocks


MNMD stock logo

About Mind Medicine (MindMed) (NASDAQ:MNMD) Stock

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company working to develop therapies and treatments based on psychoactive substances. The company develops novel products including psychoactive substances and digital medicine to treat brain health disorders related to psychiatry, addiction, pain, and neurology. Digital medicine is the use of technology to measure and intervene in the service of human health and is a budding industry of its own. The company has 10 compounds in pre-clinical or clinical trials and 4 are on track to advance to Phase 1. The company is headquartered in Vancouver, Canada.

Mind Medicine’s pipeline of drug candidates is based on emerging science that more than suggests psychoactive substances can be used to relieve stress and anxiety disorders in the brain. Among the many potential uses for these drugs is the treatment of anxiety and stress related to PTSD and secondary stress disorders related to the treatment of people suffering from stress and anxiety-related disorders. Psychoactive compounds have also been shown to be effective in treating autism, pain, and social disorders.

The company’s treatments are focused on neuroplasticity or the fact our brain function is tied to its structure and the structure of our brains can change over time. When used in the proper context, Mind Medicine’s treatments aid the restructuring of brain activity and how it organizes information by catalyzing plasticity. In some cases, patients under treatment learn to make positive associations in relation to stress-inducing stimuli while under the influence of the treatments.

In addition to plasticity, psychoactive drugs like LSD, psilocybin, and DMT have been shown to have experiential effects such as lowering mental barriers and reducing defensive and often reflexive mechanisms that can be an impediment to healing.

Among the benefits of using psychoactive compounds versus traditional therapeutics are the speed of efficacy and greatly reduced side effects. Psychoactive drugs can produce positive effects in patients with the first use while it may take weeks for the current treatments to take effect and they come with many side effects. In some cases, side effects of mainstream treatments include an increase in suicidal behavior.

The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain. MM-120 is LSD D-tartrate. MM-110 is a nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal.

Mind Medicine also develops MM-402 which is for the treatment of core symptoms of autism spectrum disorder. This treatment is based on MDMA and improves sociability in autistic patients without stimulants and is shown to have superior safety and tolerability.

 

Receive MNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter.

MNMD Stock News Headlines

MNMD - Mind Medicine (MindMed) Inc.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
MindMed to Participate in May Investor Conferences
See More Headlines
Receive MNMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mind Medicine (MindMed) and its competitors with MarketBeat's FREE daily newsletter.

MNMD Company Calendar

Last Earnings
5/04/2023
Today
5/29/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medicinals & botanicals
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MNMD
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$26.67
High Stock Price Forecast
$75.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+653.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-56,800,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.97 per share

Miscellaneous

Free Float
37,781,000
Market Cap
$136.64 million
Optionable
Not Optionable
Beta
2.05

Key Executives

  • Mr. Robert Barrow (Age 34)
    CEO & Director
    Comp: $708.41k
  • Dr. Miriam Halperin Wernli Ph.D. (Age 70)
    Exec. Pres
    Comp: $552.46k
  • Dr. Daniel Rollings Karlin M.A. (Age 43)
    M.D., Chief Medical Officer
    Comp: $493.21k
  • Dr. Scott M. Freeman M.D. (Age 66)
    Co-Founder & Clinical Advisor
  • Mr. Leonard Latchman
    Co-founder
  • Mr. Schond L. Greenway (Age 51)
    Chief Financial Officer
  • Ms. Carrie F. Liao CPA
    CGMA, VP, Corp. Controller & Accounting Principal
  • Ms. Wong Hu J.D. (Age 53)
    Chief Legal Officer & Corp. Sec.
  • Dr. Francois P. Lilienthal M.B.A.
    M.D., Chief Commercial Officer













MNMD Stock - Frequently Asked Questions

Should I buy or sell Mind Medicine (MindMed) stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mind Medicine (MindMed) in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNMD shares.
View MNMD analyst ratings
or view top-rated stocks.

What is Mind Medicine (MindMed)'s stock price forecast for 2023?

8 equities research analysts have issued 1-year price targets for Mind Medicine (MindMed)'s shares. Their MNMD share price forecasts range from $5.00 to $75.00. On average, they anticipate the company's stock price to reach $26.67 in the next year. This suggests a possible upside of 653.3% from the stock's current price.
View analysts price targets for MNMD
or view top-rated stocks among Wall Street analysts.

How have MNMD shares performed in 2023?

Mind Medicine (MindMed)'s stock was trading at $2.20 on January 1st, 2023. Since then, MNMD shares have increased by 60.9% and is now trading at $3.54.
View the best growth stocks for 2023 here
.

When is Mind Medicine (MindMed)'s next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our MNMD earnings forecast
.

How were Mind Medicine (MindMed)'s earnings last quarter?

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) announced its quarterly earnings results on Thursday, May, 4th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.10.

When did Mind Medicine (MindMed)'s stock split?

Mind Medicine (MindMed)'s stock reverse split before market open on Monday, August 29th 2022. The 1-15 reverse split was announced on Monday, August 29th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Mind Medicine (MindMed)'s stock symbol?

Mind Medicine (MindMed) trades on the NASDAQ under the ticker symbol "MNMD."

Who are Mind Medicine (MindMed)'s major shareholders?

Mind Medicine (MindMed)'s stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.89%), Two Sigma Investments LP (0.44%), Group One Trading L.P. (0.00%), State Street Corp (0.32%), AdvisorShares Investments LLC (0.25%) and Renaissance Technologies LLC (0.15%). Insiders that own company stock include Dan Karlin and Robert Barrow.
View institutional ownership trends
.

How do I buy shares of Mind Medicine (MindMed)?

Shares of MNMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mind Medicine (MindMed)'s stock price today?

One share of MNMD stock can currently be purchased for approximately $3.54.

How much money does Mind Medicine (MindMed) make?

Mind Medicine (MindMed) (NASDAQ:MNMD) has a market capitalization of $136.64 million. The company earns $-56,800,000.00 in net income (profit) each year or ($1.8297) on an earnings per share basis.

How can I contact Mind Medicine (MindMed)?

The official website for the company is www.mindmed.co. The company can be reached via phone at 650-208-2454 or via email at ir@mindmed.co.

This page (NASDAQ:MNMD) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -